Back in 2017 there was a paper from Duke, NC:
"Acute Myeloid Leukemia After Olaparib Treatment in Metastatic Castration-Resistant Prostate Cancer"
"Poly(adenosine diphosphate-ribose) polymerase (PARP) in- hibitors exploit defects in DNA repair to induce tumor-selective cytotoxicity and are in clinical development for treatment of pros- tate cancer. However, these agents may have lethal toxicities. This report highlights a serious adverse event after the use of a PARP inhibitor for a patient with metastatic castration resistant prostate cancer. Our patient had a complete response on olaparib treatment for prostate cancer, but developed likely treatment-related acute myeloid leukemia. Long term safety monitoring will be necessary in discussing clinical risks and benefits of PARP inhibitors for patients with genetically susceptible tumors."
I don't recall it creating a stir.
Now we have a French study [2] (not PCa-specific):
"Myelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors: a safety meta-analysis of randomised controlled trials and a retrospective study of the WHO pharmacovigilance database"
"The incidence of myelodysplastic syndrome and acute myeloid leukaemia across PARP inhibitor groups was 0·73% (... 21 events out of 4533 patients) and across placebo groups was 0·47% (... three events out of 2774 patients)."
Although the risk factor is 2.63, the numbers are very small. The added risk is only 0.26% (1 in 385). But something to be aware of.
-Patrick
PARP Inhibitors ??
PARP inhibitors - which one?
Erleada in the EU for metastatic prostate cancer
Clarity Update: Complete response in first patient ever treated with 2 doses of Cu-67 SAR-bisPSMA at 8GBq
